"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in this website by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 3 | 5 |
| 2012 | 4 | 2 | 6 |
| 2013 | 0 | 4 | 4 |
| 2014 | 4 | 4 | 8 |
| 2015 | 2 | 9 | 11 |
| 2016 | 7 | 8 | 15 |
| 2017 | 4 | 16 | 20 |
| 2018 | 6 | 15 | 21 |
| 2019 | 10 | 16 | 26 |
| 2020 | 17 | 25 | 42 |
| 2021 | 8 | 25 | 33 |
| 2022 | 4 | 40 | 44 |
| 2023 | 2 | 35 | 37 |
| 2024 | 11 | 24 | 35 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations. Neuro Oncol. 2025 Feb 10; 27(2):352-368.
-
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma. Proc Natl Acad Sci U S A. 2025 Jan 28; 122(4):e2319474122.
-
ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis. Cancer Res. 2025 Jan 15; 85(2):299-313.
-
Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer Discov. 2025 Jan 13; 15(1):162-178.
-
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy? Neuro Oncol. 2025 Jan 12; 27(1):33-49.
-
OSBPL3 modulates the immunosuppressive microenvironment and predicts therapeutic outcomes in pancreatic cancer. Biol Direct. 2025 Jan 09; 20(1):5.
-
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2025 Jan 07; 39(1-2):36-63.
-
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025 Jan 13; 43(1):69-85.e11.
-
An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup. Sci Transl Med. 2025 Jan; 17(779):eadr2012.
-
HER2-Positive Breast Cancer Treatment and Resistance. Adv Exp Med Biol. 2025; 1464:495-525.